North America PARP Inhibitor Biomarkers Market Size, Share & Trends Analysis Report By Product (Kits, and Assays), By Application, By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others), By Country and Growth Forecast, 2024 - 2031

North America PARP Inhibitor Biomarkers Market Size, Share & Trends Analysis Report By Product (Kits, and Assays), By Application, By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others), By Country and Growth Forecast, 2024 - 2031


The North America PARP Inhibitor Biomarkers Market would witness market growth of 7.8% CAGR during the forecast period (2024-2031).

The US market dominated the North America PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $479.7 Million by 2031. The Canada market is experiencing a CAGR of 10.3% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 9.3% during (2024 - 2031).

The market refers to the sector within the healthcare industry focused on developing, commercializing, and utilizing biomarker testing technologies and services specifically related to PARP (poly (ADP-ribose) polymerase) inhibitors.

Moreover, these are a class of anticancer drugs that target enzymes involved in DNA repair processes, particularly in cancer cells with deficiencies in other DNA repair pathways, such as BRCA1 and BRCA2 mutations.

Higher healthcare expenditure may result in increased funding for healthcare infrastructure, including diagnostic laboratories and testing facilities in Canada. This can lead to improved access to biomarker testing services, including it, for patients across Canada. Increased availability of biomarker testing can facilitate earlier detection of biomarker-defined patient populations eligible for this therapy, thereby driving market growth.

Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others.Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • NeoGenomics Laboratories
  • Qiagen N.V
  • Agilent Technologies, Inc.
  • Merck KGaA
  • Bayer AG
  • AstraZeneca PLC
  • GlaxoSmithKline PLC (GSK)
North America PARP Inhibitor Biomarkers Market Report Segmentation

By Product
  • Kits
  • Assays
By Application
  • Breast Cancer
  • Ovarian Cancer
  • Others
By Services
  • BRCA 1 & 2 Testing
  • HRD Testing
  • HRR Testing
  • Others
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America PARP Inhibitor Biomarkers Market, by Product
1.4.2 North America PARP Inhibitor Biomarkers Market, by Application
1.4.3 North America PARP Inhibitor Biomarkers Market, by Services
1.4.4 North America PARP Inhibitor Biomarkers Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis
Chapter 4. North America PARP Inhibitor Biomarkers Market by Product
4.1 North America Kits Market by Region
4.2 North America Assays Market by Region
Chapter 5. North America PARP Inhibitor Biomarkers Market by Application
5.1 North America Breast Cancer Market by Country
5.2 North America Ovarian Cancer Market by Country
5.3 North America Others Market by Country
Chapter 6. North America PARP Inhibitor Biomarkers Market by Services
6.1 North America BRCA 1 & 2 Testing Market by Country
6.2 North America HRD Testing Market by Country
6.3 North America HRR Testing Market by Country
6.4 North America Others Market by Country
Chapter 7. North America PARP Inhibitor Biomarkers Market by Country
7.1 US PARP Inhibitor Biomarkers Market
7.1.1 US PARP Inhibitor Biomarkers Market by Product
7.1.2 US PARP Inhibitor Biomarkers Market by Application
7.1.3 US PARP Inhibitor Biomarkers Market by Services
7.2 Canada PARP Inhibitor Biomarkers Market
7.2.1 Canada PARP Inhibitor Biomarkers Market by Product
7.2.2 Canada PARP Inhibitor Biomarkers Market by Application
7.2.3 Canada PARP Inhibitor Biomarkers Market by Services
7.3 Mexico PARP Inhibitor Biomarkers Market
7.3.1 Mexico PARP Inhibitor Biomarkers Market by Product
7.3.2 Mexico PARP Inhibitor Biomarkers Market by Application
7.3.3 Mexico PARP Inhibitor Biomarkers Market by Services
7.4 Rest of North America PARP Inhibitor Biomarkers Market
7.4.1 Rest of North America PARP Inhibitor Biomarkers Market by Product
7.4.2 Rest of North America PARP Inhibitor Biomarkers Market by Application
7.4.3 Rest of North America PARP Inhibitor Biomarkers Market by Services
Chapter 8. Company Profiles
8.1 Myriad Genetics, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.2 Thermo Fisher Scientific, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 SWOT Analysis
8.3 Illumina, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segment and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 SWOT Analysis
8.4 Neogenomics, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 Qiagen N.V.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Agilent Technologies, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 SWOT Analysis
8.7 Merck KGaA
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Bayer AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 AstraZeneca PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. GlaxoSmithKline PLC (GSK)
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings